Helper T lymphocyte precursor (HTLp) frequencies determined by limiting dilution analysis were studied in the graft-versus-host direction to assess the predictive value for outcome in allogeneic BMT. The HTLp frequencies correlated with the degree of HLA disparity. HTLp frequencies from 28 HLA-identical sibling BMT pairs had a median of 1:557 362 (range 1:9511 to Ͻ1:2 500 000). The HTLp frequencies from 20 HLAmatched unrelated and partially HLA-matched related BMT pairs had a median of 1:88 110 (range 1:4139-1:736 123). The HLA-identical sibling BMT pairs were split evenly into high and low HTLp frequency groups above and below 1:500 000. There was a trend towards a higher risk for acute GVHD уgrade II (P = 0.075) in the high frequency group. There was no difference in TRM. The high HTLp frequency group had a significantly higher risk for chronic GVHD (P = 0.04), a significantly lower risk for relapse (P = 0.01), as well as a significantly better overall survival (P = 0.045) and leukaemia-free survival (P = 0.008). The HLA-matched unrelated and partially HLA-matched related BMT pairs were split evenly into high and low HTLp frequency groups above and below 1:90 000. There was a significantly higher risk for acute GVHD уgrade II (P = 0.007) in the high HTLp frequency group. There was a trend towards a higher TRM in the high HTLp frequency group (P = 0.05). There were no differences in chronic GVHD, risk of relapse, overall survival and leukaemia-free survival. Analyzing all 48 patients the risk of acute GVHD уgrade II and TRM was significantly higher (P = 0.012 and 0.021, respectively) with HTLp frequencies Ͼ1:100 000 and there was a trend towards a higher risk of relapse (P = 0.058) with low HTLp frequencies Ͻ1:400 000. Patients in the intermediate HTLp frequency group 1:100 000-1:400 000 had a trend towards improved survival (P = 0.059). The HTLp frequency seems to detect clinically significant differences in alloreactivity, that can be useful in donor 
Graft-versus-host disease (GVHD) and graft-versus-leukaemia (GVL) effects are manifestations of alloreactivity.
There is a correlation between GVHD and GVL in human allogeneic bone marrow transplantation (BMT) and both are important factors for clinical outcome. 1 Severe GVHD is one of the main causes of morbidity and mortality post BMT. In the absence of GVL, the risk of relapse is high. Disparity in major histocompatibility complex (MHC) antigens increases the risk of GVHD. 2 In BMT with identity of the MHC antigens the risk of GVHD is reduced, but significant GVHD still occurs in approximately 35% of the recipients transplanted with a human leukocyte antigen (HLA) identical sibling donor. 3 This is due to mismatches for minor histocompatibility antigens (mHag), where only few have been characterized and not all are associated with GVHD. 4 Other methods than tissue typing capable of predicting alloreactivity will have the potential of improving the outcome after allogeneic BMT. Determination of donor helper T lymphocyte precursor (HTLp) frequencies directed against the recipient has been demonstrated to be predictive for acute GVHD in the context of HLA-identical sibling BMT. [5] [6] [7] [8] [9] Three reports have not found this correlation. [10] [11] [12] In the unrelated BMT setting the predictive value of the HTLp frequency for acute GVHD has been less convincing. 13, 14 The methods for determination of HTLp frequencies by limiting dilution analysis (LDA) differ in regard to the method of detection of interleukin 2 (IL-2), culture time and the use of restimulation with Epstein-Barr virus transformed B lymphoblastoid cell lines (EBV-LCL). We have used the HTLp assay designed by Schwarer et al 6 and modified it in our laboratory with regard to detection of IL-2 and cell concentrations as previously described. [15] [16] [17] In the present study, pre-transplantation anti-recipient HTLp frequencies from 28 HLA-identical sibling BMT pairs and from 20 HLA-matched unrelated and partially HLAmatched related BMT pairs were determined. The predictive value of the HTLp frequency for acute GVHD уgrade II, chronic GVHD, treatment-related mortality (TRM), relapse, overall survival and leukaemia-free survival (LFS) were analysed for the two groups and for all patients together.
Recipients, materials and methods

Characteristics of the recipients (Tables 1 and 2)
The recipients were transplanted from August 1993 to June 1997. The median follow-up for recipients alive was 4.5 years (range 3-6.5 years) calculated from transplantation to last visit at the BMT unit before May 2000. The patients were transplanted with unmanipulated bone marrow except for depletion of red blood cells in case of ABO blood group major mismatch. In the HLA-identical sibling BMT pairs the median age was 36 years (range 17-55 years). There were two recipients younger than 20 years. The median age of the donors was 34 years (ranged 15-59 years). In the MUD and partially HLA-matched group the median age was 28.5 years (range 14-50 years). Five recipients were below 20 years of age. The median age of the donors was 37 years (range 21-74 years). Four male recipients were transplanted with an HLA-identical female donor potentially sensitised by pregnancy. Five recipients in the MUD and partially HLA-matched group had a donor potentially sensitised by pregnancy or blood transfusion. Cytomegalo- Table 1 Characteristics for HLA-identical sibling transplantations (n = 28) The patients who developed acute GVHD grade уII received methylprednisolone at a starting dose of 2 mg/kg/day. Acute and chronic GVHD were diagnosed according to standard clinical and histopathological criteria. 18 Relapse was defined as haematological and/or cyto- Alive, CR UTN = unique transplant number; TBI = total body irradiation (12 Gy fractionated); TBI + testicular = total body irradiation + testicular irradiation (12 Gy +4 Gy); TBI + cranial = total body irradiation and cranial irradiation (12 Gy + 10 Gy); TBI + testicular = total body irradiation, testicular and cranial irradiation (12 Gy of TBI, 4 Gy and 10 Gy); Cy = cyclophosphamide; Bu = busulphan; ATG = anti-thymocyte globuline; MUD = HLA-matched unrelated donor; ⊕ = partially HLA-matched related donor; C? = C locus not tested; incl C = matched at C locus; → = mismatch in the HVG direction; ← = mismatch in the GVH direction; ↔ = mismatch in both the GVH and HVG direction; CR = complete remission; NR = no response; * = treated with donor leukocyte infusion; ** = given second marrow infusion from original donor.
UTN
genetic relapse. Molecular evidence of relapse for the bcrabl translocation or other leukaemia-specific translocations was not used. TRM was defined as any cause of death other than relapse. The patients treated with donor leukocyte infusion (DLI) or with a second bone marrow infusion from the same donor were followed until death or last followup before May 2000. The clinical data were collected and included in the database of the BMT unit without knowledge of the results of the HTLp frequency determinations.
HLA typing
HLA typing for HLA-A, -B, -C was performed using the standard microcytotoxic assay. 19 All healthy volunteers but two were typed for HLA-A, -B and -DR. HLA-C was determined for 24 of 28 HLA-identical sibling transplant pairs. HLA-DR genotyping was performed by sequencespecific primer polymerase chain reaction (Dynal, Oslo, Norway) in 21 of the 28 HLA-identical sibling transplant pairs. 20 Family studies were performed when possible.
Preparation of mononuclear cells
Mononuclear cells (MNC) were isolated by gradient centrifugation (Lymphoprep (density 1.077 g/l); Nycomed Pharma, Oslo, Norway) of heparinized peripheral blood from healthy volunteers and patients and donors. The blood was obtained after written informed consent. The MNC were frozen in 50% RPMI 1640 medium with 100 IU/ml Bone Marrow Transplantation penicillin, 100 g/ml streptomycin and 2 mm l-glutamine (all from GIBCO, Life Technologies, Roskilde, Denmark), 40% heat-inactivated autologous serum and 10% dimethylsulfoxide (Merck, Darmstadt, Germany) in a 2-propanolol containing freezing container (Nalgene; Struers Kebo Lab, Albertslund, Denmark) to ensure a controlled cooling in −80°C freezer overnight and moved to liquid nitrogen for later use. Before the MNC were used in the HTLp assay, the cells were rapidly thawed and washed three times in RPMI 1640 medium supplemented with 100 IU/ml penicillin, 100 g/ml streptomycin and 2 mm l-glutamine referred to as culture medium from here.
HTLp assay
Pre-transplantation HTLp frequencies were determined in the GVH direction. The assay was based on the method of Schwarer et al 6 with our modifications. [15] [16] [17] Graded numbers of donor MNC were stimulated with 10 5 recipient MNC. The recipient MNC were irradiated with 50 Gy ( ). The changes in the number of repli-cates and dilutions were made after we had shown that the simpler experiment with six dilutions resulted in a coefficient of variation for the HTLp frequency determination as good as the experiment with 10 dilutions. 17 Twenty-four replicates with irradiated recipient cells alone served as background controls. The capacity of the recipient cells to stimulate was tested with HLA-mismatched third party cells as responders. The capacity of the donor cells to respond was tested against irradiated HLA-mismatched third party cells in culture medium with 10% heat-inactivated third party serum. The autoreactivity of the donor cells was tested with unirradiated plus irradiated responder cells in culture medium with 10% heat-inactivated responder serum. The cells were cultured at 37°C in 7.5% CO 2 for 3 days. The microtiter plates were irradiated either with a dose of 25 Gy of X rays in a linear accelerator (8 MV; Varian Electronics, Palo Alto, CA; USA) or with a dose of 2.0 J/cm 2 of UV-B radiation (seven Philips TL12 tubes (Philips Denmark, Copenhagen, Denmark) emitting a flux of 4.65 mW per cm 2 at 280-360 nm). 16 UV-B irradiation was performed in a laminar flow hood with the lids off the microtiter plates. The change to UV-B irradiation was chosen because of restricted access to the linear accelerator and following validation of UV-B radiation for proliferation termination as previously described. 16 Ten thousand CTLL-2 cells, deprived of IL-2 for 24 h before use, were added to the microtiter plates immediately after irradiation and 3 H-methyl-thymidine (TRK 637; Amersham, Buckinghamshire, UK) was added after 6 h. 15 A series of IL-2 dilutions was included in each assay to confirm optimal sensitivity (0.6 pg/well) of the CTLL-2 cells. 15 The microtiter plates were incubated overnight at 37°C in 7.5% CO 2 and then harvested on to glass fiber filters with a 96-well cell harvester (Filter Mate; Packard Instrument Company, Meriden, CT, USA). ␤ Emission was determined as counts per minute (c.p.m.) with a direct ␤ counter (Matrix 9600; Packard Instrument).
HTLp statistics
Wells were defined as positive if c.p.m. were above the mean of c.p.m. plus 3 s.d. of the wells with recipient cells alone. HTLp frequencies were calculated by the maximum likelihood method. A P value above 0.05 indicated an acceptable fit to the model. 21 A stimulator index was calculated by dividing the mean of c.p.m. of the control wells by the mean of c.p.m. of the wells with irradiated recipient cells alone. HTLp experiments with a stimulator index Ͻ2.5 for stimulation capability and responding capability were included in the study. The results of the autologous donor control did not disqualify the analysis, because there was no correlation between HTLp frequencies and extent of donor autoreactivity and the extent of donor autoreactivity did not correlate to clinical outcome of the patients (Russell et al, in press ). The coefficient of variation of HTLp frequency determination increases with decreasing HTLp frequency and was estimated as approximately 25% at a frequency of 1:1 500 000. 17 HTLp frequencies below 1:2 500 000 were scored as Ͻ1:2 500 000.
The age of the recipients and donors in the groups was compared with the Mann-Whitney test. The HTLp frequencies in HLA-mismatched, in MUD and partially HLAmatched related and in HLA-identical sibling pairs were compared using one-way analysis of variance (KruskalWallis test). The HTLp frequencies determined after X irradiation and UV-B irradiation in HLA-identical sibling pairs was compared with the Mann-Whitney test. The cumulative incidence curves were compared by the log rank test. All comparisons were made in GraphPad Prism 3.0 (GraphPad Software, San Diego, CA, USA).
Results
Termination of proliferation of the responder cells in LDA
The termination of proliferation of the responder cells in the HTLp determinations after 3 days of culture was initially done in a linear accelerator with 24 replicates of 10 dilutions based on the method of Schwarer et al. 6 Later we used UV-B radiation of the HTLp assays with 48 replicates of six dilutions, which is a simpler procedure and eliminates the risk of continuous proliferation of the responder cells. 16, 17 For the HLA-identical sibling BMT pairs, 10 assays of HTLp frequencies were done after irradiation in linear accelerator and 18 assays after UV-B irradiation. The two groups were not significantly different (P = 0.24, Mann-Whitney test). The HTLp frequencies of the different termination methods were therefore analyzed together.
HTLp frequencies and HLA disparity (Figure 1)
HTLp frequencies from 18 pairs of three to six loci HLAmismatched unrelated healthy volunteers were compared with the HTLp frequencies from 20 MUD and partially HLA-matched related BMT pairs and with the HTLp frequencies from 28 HLA-identical sibling BMT pairs. The medians of the HTLp frequencies of the three groups were different (1:18 000, 1:88 000, 1:557 000, respectively), but the ranges were overlapping. Comparison of the HTLp fre- Figure 2) The 28 assays of HTLp frequency from HLA-identical sibling pairs were split evenly in a high HTLp frequency group with frequencies Ͼ1:500 000 and a low HTLp frequency group with frequencies Ͻ1:500 000. There were no significant differences between the groups in terms of age, donor/recipient gender, CMV serostatus, diagnosis or disease risk at time of transplantation. Six patients developed Bone Marrow Transplantation clinically significant acute GVHD (21%). Four patients had grade II and two patients had grade III acute GVHD. There was a trend towards more acute GVHD in the high HTLp frequency group (P = 0.075) (Figure 2a) . The patients at risk for developing chronic GVHD (surviving Ͼ100 days) showed significantly more chronic GVHD in the high frequency group (P = 0.038) (Figure 2b ). Five patients died of complications to the transplantation procedure. One patient died of acute GVHD grade III involving skin and liver, two patients died of infection, one patient died of cerebral complications of unknown origin 1. years after BMT with only limited chronic GVHD and one patient died of pulmonary haemorrhage. There was no difference in TRM (Figure 2c ). Eleven of the 28 patients relapsed, one of them 5 years post BMT. Seven of the patients with relapse were treated with DLI. Three of them are alive, two in complete remission and one with stable disease. The low HTLp frequency group had a significantly higher risk of relapse (P = 0.012) (Figure 2d ). The patients transplanted with a donor with high anti-recipient reactivity had a significantly better overall survival (P = 0.045) and a significantly better LFS (P = 0.008) (Figure 2e and f) . The results indicate that HTLp determination with LDA can detect clinically significant mHag differences and the HTLp frequency for a given donor/recipient combination seems to be a strong predictor of the GVL effect in HLA-identical sibling transplantations.
MUD and partially HLA-matched related transplants (Table 2 and Figure 3)
The 20 HTLp determinations were split evenly in a high HTLp frequency with frequencies Ͼ1:90 000 and a low HTLp frequency group with frequencies Ͻ1:90 000. There were no significant differences between the groups in terms of donor/recipient age and gender, CMV serostatus, disease risk at time of transplantation. There were four patients with CML (three in 1.CP and one in 2.CP) in the high HTLp frequency group and no patients with CML in the low HTLp frequency group. All patients in the high HTLp frequency group developed acute GVHD уgrade II. Six of 10 patients in the low HTLp frequency group developed GVHD уgrade II resulting in a significantly higher risk for acute GVHD уgrade II in the high frequency group (P = 0.007) (Figure 3a) . Eleven of 15 patients surviving more than 100 days after transplantation developed chronic GVHD. Nine patients had extensive chronic GVHD and two limited chronic GVHD. There was no difference in the risk for chronic GVHD between the two groups ( Figure 3b) . Two patients died of thrombotic thrombocytopenic purpura, two patients died of GVHD, two patients died of infection, three patients died of graft failure, one patient died of cerebral complications of unknown origin and one patient committed suicide. The high frequency group had a trend towards higher TRM (P = 0.054) (Figure 3c ). Three patients were given a second bone marrow infusion from the same donor due to secondary graft failure. One of them had a C locus mismatch in the rejection direction. For the other two patients the C locus was unknown. Four patients relapsed, 7 months to 3. years post BMT. Three were treated with DLI, but had no response. One was retransplanted with the same donor after induction chemotherapy and has obtained a continuous complete remission. There were no significant differences between the two groups in the risk of relapse, overall survival and LFS (Figure 3d-f) .
HLA-identical, MUD and partially HLA-matched related transplants analysed together (Figure 4)
The whole group of 48 BMT pairs was analysed using the discrimination cuts for high HTLp frequencies Ͼ1:100 000, intermediate HTLp frequencies 1:100 000-1:400 000 and low HTLp frequencies Ͻ1:400 000 initially described by Schwarer et al. 6 Patients in the high HTLp frequency group had a significantly higher risk of acute GVHD уgrade II compared to the low HTLp frequency group (P = 0.006) ( Figure 4a ) and a significantly higher TRM (P = 0.021) (Figure 4c ). Patients in the low HTLp frequency group had a trend towards an increased risk of relapse compared to the high HTLp frequency group (P = 0.058) (Figure 4d ). There was a trend towards improved survival of the intermediate HTLp frequency group compared to the high frequency group (P = 0.059) (Figure 4e ).
Discussion
Acute GVHD and relapse are major causes of treatment failure after BMT. Pre-transplantation factors that are predictive for outcome, such as immunised female donor to male recipient and recipient age, have not been useful for prediction of GVHD for an individual donor/recipient pair. 3, [22] [23] [24] [25] The number of HLA disparities 2 and some mHag differences 4 have been associated with the severity of GVHD. HTLp frequency determination has been used for prediction of alloreactivity for a given donor/recipient combination, though the methods used for detection of HTLp frequencies have differed. In some studies a 14-day assay with IL-2 determination after restimulation with EBV-LCL have been used. 5, 13, 14 Others have used detection of IL-2 in the supernatant or total culture volume 1., 2 or 3 days after stimulation. [6] [7] [8] [9] 11, 12 We have used the 3-day assay based on the method of Schwarer et al 6 with our modifications [15] [16] [17] and have found HTLp frequencies with a median of 1:557 000 in HLA-identical sibling BMT pairs. Some studies have used a discrimination cut off 1:100 000 between high and low HTLp frequencies, [5] [6] [7] 12 while Winandy et al 9 have used a discrimination cut off at 1:150 000 and Lachance et al 8 have used a discrimination cut off at 1:200 000. Wang et al 12 found a median HTLp frequency of 1:321 000, but found no correlation between HTLp frequencies and acute GVHD with discrimination cuts at 1:100 000, 1:200 000 or 1:300 000. Eibl et al 10 have found a median HTLp frequency similar to ours (1:500 000) and in that study there was no correlation between acute GVHD and HTLp frequency. The use of autologous serum from the patient instead of pooled human sera could be an expla-nation for the lower HTLp frequencies found in our series. Foreign antigens present in pooled human sera may elicit a response from the donor cells (Russell et al, in press ). Other possible explanations include the fact that some studies looked at T cell-depleted HLA-identical sibling BMT pairs, 11 unrelated BMT pairs 13 or both unrelated and HLAidentical sibling BMT pairs 9 and some use of EBV-LCL restimulation. 5, 13 EBV-LCL restimulation may increase the apparent HTLp frequency. 26 In the MUD and partially HLA-matched BMT pairs we found a median of the HTLp frequencies of 1:90 000.
A limitation in the predictive value of HTLp frequencies determined by MNC as stimulator and responder cells relates to the tissue-specific expression of mHag. Alloreactivity can be directed against mHag expressed by haematopoietic cells only or by tissues other than haematopoietic tissues. 27 This may be an explanation for three patients with high HTLp frequencies who had no signs of clinical GVHD or relapse. These patients may have mHag differences resulting in antigen(s) expressed only by haematopoietic cells and responsible for a curative GVL effect. Conversely, one patient with an HLA-identical sibling donor with a low HTLp frequency (1:2 150 000) developed fatal grade III acute GVHD involving skin and liver. Here the antigen(s) may not have been expressed by the haematopoietic tissue and therefore not detected in the HTLp assay where MNC were used as stimulators. Another explanation could be that the alloreactive response was driven by Th2 cells rather than Th1 cells in vivo. In our HTLp assay with IL-2 detection only the Th1 response is determined. Recently, experimental data from mice have shown that Th2 responses were required for the induction of hepatic and severe skin GVHD. In contrast, both Th1 and Th2 cells were capable of causing intestinal GVHD. 28 Factors other than histoincompatibility may be responsible for GVHD and may not be detected in the HTLp frequency assay. Recipient-specific factors could remain undetected, since the MNC of the recipients are irradiated. Gene polymorphism studies of IL-10 and TNF-␣ alleles have shown a correlation with specific alleles of the patients and severe acute GVHD in HLA-identical sibling BMT. 29, 30 Low spontaneous production of IL-10 measured in MNC from patients prior to transplantation has also correlated with acute GVHD and increased TRM. 31 The impact on the GVL effect has not been addressed in these studies.
Only 21% of the patients in the HLA-identical sibling group developed acute GVHD grade уII. This low incidence combined with the limited number of patients in the study may explain why the difference in acute GVHD between the high and the low HTLp frequency group did not reach statistical significance. In studies with a significant correlation between the high HTLp frequencies and acute GVHD grade уII, 33-52% of the patients transplanted with an HLA-identical sibling donor had acute GVHD grade уII. [5] [6] [7] [8] [9] The reduced risk of acute GVHD in our series could be a result of recipient age, since recipients Ͻ20 years have been reported to have a reduced risk of acute GVHD. 3, 23, 25 However only two recipients, one in each HTLp frequency group, were younger than 20 years. Thirty-two percent of the patients in the HLA-identical cohort developed chronic GVHD with a significantly higher incidence in the high HTLp frequency group. The HTLp frequency was also predictive for GVL. The patients with an HLA-identical donor with a high frequency had a significantly reduced risk of relapse and a significantly better survival. This confirms the results of Lachance et al. 8 The correlation between higher grades of GVHD and lower risks of relapse has been documented in a report of 2254 HLA-identical sibling transplantations. 1 In the MUD and partially HLA-matched related BMT pairs, the HTLp frequencies were higher (median 1:88 000) than in HLA-identical sibling BMT pairs. The incidence of acute GVHD was significantly higher for the patients transplanted with a donor with a high HTLp frequency, but 80% of all patients had acute GVHD grade уII. There was a trend (P = 0.054) towards higher TRM in the high HTLp frequency group. This reflects that the patients often had severe acute GVHD that was fatal. There were no significant differences for chronic GVHD, risk of relapse, overall survival or LFS between the high and low HTLp frequency groups. In unrelated BMT, only a weak correlation between high HTLp frequencies and decreased survival has been found.
14 Keever-Taylor et al 13 found a positive correlation between low HTLp frequencies and survival in univariate analysis.
Data from HLA-identical sibling BMT pairs, MUD and partially HLA-matched related BMT pairs were combined and analysed for correlation between HTLp frequencies and outcome. The results are consistent with the theory that patients in the intermediate HTLp frequency group (range 1:100 000-1:400 000) have the best survival while patients in the high frequency group suffer TRM (GVHD), whereas patients in the low frequency group have a high risk of relapse. This is of interest since an increase in alloreactivity in the low frequency group could be induced by decreasing the pharmacological immunosuppression or by an increased T cell dose. Conversely a decrease in alloreactivity in the high frequency group could be obtained by in vivo or ex vivo T cell depletion. Alternatively if more donors are available the HTLp frequency can be used as a selection criterion.
In conclusion our results indicate that HTLp frequency determination has a predictive value for GVHD and GVL and may be a useful tool in allogeneic BMT. The study also indicates the complexity of the positive and negative effects of alloreactivity on outcome. It would probably be naive to assume that a single robust predictive parameter for alloreactivity can be found. Ideally large uniformly diagnosed, staged and treated patient populations should be examined with an array of assays with possible predictive value. The constantly evolving clinical transplant procedures and laboratory techniques make such a project difficult to accomplish.
